Astellas faces a near-term revenue cliff from Xtandi (prostate cancer) LOE, partially offset by growth drivers Veozah (menopause), Padcev (bladder cancer with Pfizer), and gene therapies. The Iveric Bio acquisition added Izervay for geographic atrophy. Pipeline transition execution is the central question, with multiple late-stage assets in oncology and rare disease. Yen translation supports reported earnings.
Thesis reviewed May 29, 2026
Astellas Pharma Inc. is headquartered in Japan, which is currently showing moderate signals.
π―π΅Japan63NEUTRALView Japan risk detail βπPharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Ξ | Action |
|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | 50 | +15% | β0% | EARLY |
| RDY | Dr Reddy's Laboratories Ltd | 50 | +7% | β0% | NEUTRAL |
| SNY | Sanofi | 50 | +14% | β0% | EARLY |
| GSK | GSK plc | 50 | +8% | β0% | NEUTRAL |
| PFE | Pfizer Inc. | 50 | +6% | β0% | NEUTRAL |
| AZN | AstraZeneca PLC | 50 | +11% | β0% | EARLY |
| LLY | Eli Lilly and Company | 50 | +24% | β0% | EARLY |
Investors who hold ALPMY may also have indirect exposure through these country funds.
Astellas Veozah uptake accelerates in US menopause market
Padcev expansion in 1L bladder cancer drives oncology revenue
Estimates Β· Yahoo Finance Β· Not audited figures